ライフサイエンスコーパス: thromboembolism

1 pulmonary embolism), and raloxifene (venous thromboembolism).

2 deep-vein thrombosis and symptomatic venous thromboembolism.

3 leeding without increased risk for recurrent thromboembolism.

4 er than those used for prophylaxis of venous thromboembolism.

5 th warfarin in the treatment of acute venous thromboembolism.

6 tagonists during extended therapy for venous thromboembolism.

7 l anticoagulants for the treatment of venous thromboembolism.

8 analysis of heart failure and risk of venous thromboembolism.

9 the treatment of patients with acute venous thromboembolism.

10 risk factor for stroke and systemic arterial thromboembolism.

11 n the management of cancer-associated venous thromboembolism.

12 re disease, have an increased risk of venous thromboembolism.

13 vascular accident, rebleeding, pneumonia, or thromboembolism.

14 a common independent risk factor for venous thromboembolism.

15 bosis and pulmonary embolism comprise venous thromboembolism.

16 tal had an RR of 1.51 (1.36-1.68) for venous thromboembolism.

17 treatment for prevention of recurrent venous thromboembolism.

18 medical devices, is a strong risk factor for thromboembolism.

19 on through a multi-lumen PICC, 61 had venous thromboembolism.

20 ntiphospholipid syndrome and previous venous thromboembolism.

21 se middle cerebral artery sign and pulmonary thromboembolism.

22 of ventricular septal defect and paradoxical thromboembolism.

23 n patients who had a first unprovoked venous thromboembolism.

24 edoxaban is narrower for major bleeding than thromboembolism.

25 mong patients with a first unprovoked venous thromboembolism.

26 substantial increase in stroke and systemic thromboembolism.

27 elopments in the imaging diagnosis of venous thromboembolism.

28 otal of 289 patients (7.7%) developed venous thromboembolism.

29 iagnosis of experimentally induced pulmonary thromboembolism.

30 ndard treatment for cancer-associated venous thromboembolism.

31 a beneficial effect of statin use on venous thromboembolism.

32 tially increased short-term risk of arterial thromboembolism.

33 patients with atrial fibrillation and venous thromboembolism.

34 t cases and is associated with a low risk of thromboembolism.

35 atrial fibrillation and management of venous thromboembolism.

36 ive for the prevention of symptomatic venous thromboembolism.

37 valvular heart disease HR 1.23 (1.05-1.44), thromboembolism 1.32 (1.17-1.49), congestive heart failu

38 ke (11 more cases [95% CI, 2 to 23]), venous thromboembolism (11 more cases [95% CI, 3 to 22]), and u

39 us, and stroke, transient ischemic attack or thromboembolism [2 points]-vascular disease, and sex cat

40 ore cases [95% CI, 606 to 1168]), and venous thromboembolism (21 more cases [95% CI, 12 to 33]).

41 -four (65%) had a superior mesenteric artery thromboembolism, 25 (22%) had a superior mesenteric vein

42 e marrow function; adequately anticoagulated thromboembolism; a urine protein to creatinine ratio of

43 Outcomes were venous thromboembolism, acute myocardial infarction, ischemic s

44 was a significantly increased risk of venous thromboembolism (adjusted HR 1.24, 95% CI 1.01-1.52; p=0

45 No patients have exhibited thromboembolism after 842+/-338 days post ligation.

46 ylaxis to prevent clinically apparent venous thromboembolism after knee arthroscopy or casting of the

47 -term anticoagulation is required to prevent thromboembolism after MHV replacement, its value in pati

48 compared the incidence of symptomatic venous thromboembolism after these procedures between patients

49 7 and 2012 were followed up for diagnosis of thromboembolism and arterial events.

50 eight heparin for the prevention of arterial thromboembolism and decreased the risk of major bleeding

51 investigated the association between venous thromboembolism and heart failure, but have yielded inco

52 vels of FXI have been associated with venous thromboembolism and ischemic stroke, its deficiency is a

53 cumulative incidences of symptomatic venous thromboembolism and major bleeding within 3 months after

54 drug efficacy and probability of HIT-related thromboembolism and major bleeding.

55 rombosis provides a substrate for subsequent thromboembolism and may identify a reversible cause of p

56 ticoagulation for indications such as venous thromboembolism and mechanical heart valves.

57 rs in tumor vessels promote tumor-associated thromboembolism and metastasis.

58 Venous thromboembolism and mortality each occurred in one patie

59 Clinical disease manifestations include thromboembolism and neuropsychiatric, ocular, and skelet

60 Grade 3/4 venous thromboembolism and peripheral neuropathy were rare (1.6

61 ated procoagulatory activity leads to venous thromboembolism and supports metastasis in cancer patien

62 ears of age who had not had cancer or venous thromboembolism and who had not received treatment for i

63 for the prevention of perioperative arterial thromboembolism and would be superior to bridging with r

64 tal SSPE is associated with recurrent venous thromboembolism and, when symptomatic, may adversely imp

65 tcomes were major bleeding, recurrent venous thromboembolism, and all-cause mortality.

66 ts without AF, the risks of ischemic stroke, thromboembolism, and death were 3.1% (n = 977), 9.9% (n

67 Ischemic stroke, thromboembolism, and death within 1 year after HF diagno

68 was associated with risk of ischemic stroke, thromboembolism, and death.

69 plications within atherosclerosis and venous thromboembolism, and explores the potential for metaboli

70 ed patients with atrial fibrillation, venous thromboembolism, and mechanical valve replacement.

71 enous thrombosis, pulmonary embolism, venous thromboembolism, and myocardial infarction by developing

72 ons, such as urinary tract infection, venous thromboembolism, and myocardial infarction, on these out

73 , heart failure, arrhythmias, stroke, venous thromboembolism, and peripheral vascular disease.

74 rotoxicity, sinusoidal obstructive syndrome, thromboembolism, and Pneumocystis jirovecii pneumonia) t

75 ncy, urinary tract infection, stroke, venous thromboembolism, and postoperative death continued to be

76 sepsis, hospital acquired infections, venous thromboembolism, and pulmonary embolism.

77 mptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was ma

78 fibrillation and for the treatment of venous thromboembolism, and they are comparable to low-molecula

79 with a personal or family history of venous thromboembolism, and those receiving vasopressors.

80 lusion required reporting of maternal death, thromboembolism, and valve failure, and/or fetal spontan

81 reatment of patients with cancer with venous thromboembolism, and with less clinically relevant bleed

82 heir contribution to the incidence of venous thromboembolism are not well understood in the clinical

83 comes attributed to AF, including stroke and thromboembolism, are well established, and epidemiology

84 n autoimmune disease characterized by venous thromboembolism, arterial thrombosis, and obstetric morb

85 efficacy outcome was the incidence of venous thromboembolism (assessed by mandatory bilateral venogra

86 anticoagulant licensed for the prevention of thromboembolisms associated with orthopedic surgery and

87 analysis, the incidence of recurrent venous thromboembolism at 3 months was 1.1% (0.8-1.4; 44 of 411

88 d with a slightly increased risk of arterial thromboembolism (ATE).

89 the cumulative incidence of recurrent venous thromboembolism between 3 and 12 months was 0.3% (95% CI

90 ls, collected as part of the Swedish "Venous Thromboembolism Biomarker Study," using suspension bead

91 en suggested as a new risk factor for venous thromboembolism, but its prognostic value is unclear.

92 treatment and secondary prevention of venous thromboembolism, but whether it is useful in patients wi

93 der than 65 years, male sex, previous venous thromboembolism, cancer, autoimmune disease, thrombosis

94 actures, peripheral arterial disease, venous thromboembolism, cardiac-related complications, diabetes

95 Stent thrombosis and thromboembolism caused ALI in 13% and 5%, respectively.

96 cts of aspirin, such as prevention of venous thromboembolism, chemoprevention of colorectal (and othe

97 osuvastatin having the lowest risk on venous thromboembolism compared with other statins 0.57 (0.42-0

98 th rosuvastatin significantly reduced venous thromboembolism compared with other statins.

99 catheters (PICCs) affects the risk of venous thromboembolism compared with transfusion through non-PI

100 sistant to collagen- and epinephrine-induced thromboembolism compared with wild-type mice and showed

101 patients with atrial fibrillation or venous thromboembolism, compared a novel oral anticoagulant (da

102 Venous thromboembolism complications in-hospital and up to 90 d

103 hile non-pulmonary conditions include venous thromboembolism, coronary artery disease, congestive hea

104 ed the association of statin use with venous thromboembolism, deep vein thrombosis, or pulmonary embo

105 or no treatment and collected data on venous thromboembolism, deep vein thrombosis, or pulmonary embo

106 of adjudicated symptomatic recurrent venous thromboembolism defined as a composite of deep vein thro

107 agnosis codes were used to identify arterial thromboembolism, defined as myocardial infarction or isc

108 Venous thromboembolism developed in 482 (5%) of 10 604 patients

109 y of occurrence, complication in the form of thromboembolism, dissection and intracardiac shunting an

110 etes, stroke or transient ischemic attack or thromboembolism [doubled], vascular disease [prior myoca

111 , diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior myoca

112 e patients with symptomatic recurrent venous thromboembolism during the 12-month study period, analys

113 of adjudicated symptomatic recurrent venous thromboembolism evaluated for each of the time intervals

114 mbogenic atrial substrate can lead to atrial thromboembolism even in the absence of atrial fibrillati

115 ich statins are associated with first venous thromboembolism events.

116 heir 3-month incidence of symptomatic venous thromboembolism (failure rate) was also estimated.

117 Rates for thromboembolism for the 'European treatment threshold' (

118 ederal California hospitals for acute venous thromboembolism from 2005 to 2010.

119 ts with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after dis

120 pproaches for patients with suspected venous thromboembolism have been developed over the years, invo

121 luded a personal or family history of venous thromboembolism (hazard ratio, 1.64; 95% CI, 1.03-2.59;

122 ripheral arterial disease (HR, 2.25), venous thromboembolism (HR, 1.52), cardiac-related complication

123 utcomes: acute cardiac event; stroke; venous thromboembolism; hypertension; and diabetes mellitus, co

124 d for hypertension (I(2) = 95.0%) and venous thromboembolism (I(2) = 82.3%).

125 ral anticoagulants in prevention of arterial thromboembolism in AF, highlighting the greater absolute

126 The adjusted hazard ratio (HR) for venous thromboembolism in all patients whose transfusions were

127 Among patients with venous thromboembolism in equipoise for continued anticoagulati

128 ) is a common genetic risk factor for venous thromboembolism in humans.

129 Annual rates of any major bleeding and any thromboembolism in iTTR less than 70% were 3.81% (3.51-4

130 We also assessed rates of venous thromboembolism in patients in different settings.

131 for studies investigating the risk of venous thromboembolism in patients in hospital with heart failu

132 abetes is a well-established risk factor for thromboembolism in patients with atrial fibrillation (AF

133 r-weight heparin for the treatment of venous thromboembolism in patients with cancer are warranted.

134 The risk of arterial thromboembolism in patients with cancer is incompletely

135 absolute and relative risks (RR) for venous thromboembolism in patients with heart failure after hos

136 treatment and prevention of recurrent venous thromboembolism in patients with pulmonary embolism and

137 ranscatheter BHV replacement are at risk for thromboembolism in the first few months, and recent data

138 ase in relative efficacy to prevent arterial thromboembolism in the upper range of CrCl, the safety a

139 We assumed a 3% annual thromboembolism incidence and a non-inferiority margin o

140 s were observed for pregnancy-related venous thromboembolism (incidence rate ratio, 2.22; 95% confide

141 failure as measured by development of venous thromboembolism included a personal or family history of

142 nosed non-fatal and fatal arterial or venous thromboembolism, including myocardial infarction and tra

143 tality, multiple organ failure (MOF), venous thromboembolism, infection, stroke, ventilator-free days

144 7.5 in males and 59.5 in females; and venous thromboembolism, IR=115 to 269.

145 The reported incidence of venous thromboembolism is 1.5-3.4% of infected patients, and it

146 Venous thromboembolism is a common complication in patients wit

147 Venous thromboembolism is a common complication of cancer.

148 Venous thromboembolism is a known but rare complication associa

149 Venous thromboembolism is a major global health problem that is

150 deep venous thrombi and subsequent pulmonary thromboembolism is a serious medical challenge, since bo

151 herness of hyperdense MCA sign and pulmonary thromboembolism is extremely rare in the literature.

152 its benefit for preventing recurrent venous thromboembolism is not well known.

153 rical data from the GENEVA project on venous thromboembolism is used to illustrate the proposed tests

154 Oral anticoagulant therapy for venous thromboembolism is very effective.

155 se middle cerebral artery sign and pulmonary thromboembolism is very rare in the literature.

156 and the 1-year incidence of recurrent venous thromboembolism manifested as pulmonary embolism or deep

157 Venous thromboembolism may be the earliest sign of cancer.

158 Consistent with this, in a pulmonary thromboembolism model, larger vessels were occluded.

159 2.3; atrial fibrillation, MR=1.7; and venous thromboembolism, MR=9.4 to 32.3.

160 In patients with venous thromboembolism, no increased risk of substantial intrao

161 Venous thromboembolism occurred in 10 of the 719 patients (1.4%

162 Recurrent venous thromboembolism occurred in 11 (3%) of 414 and 20 (5%) o

163 Recurrent venous thromboembolism occurred in 14 (3%) of 465 patients in t

164 Recurrent venous thromboembolism occurred in 14 (4%) of 378 patients give

165 Recurrent venous thromboembolism occurred in 3 patients in the warfarin g

166 Recurrent venous thromboembolism occurred in 41 patients (7.9%) in the ed

167 Venous thromboembolism occurred in 5 of the 731 patients (0.7%)

168 ring the 3-month follow-up, recurrent venous thromboembolism occurred in two patients (0.73%; 95% CI,

169 Venous thromboembolism occurs commonly in patients with cancer.

170 Venous thromboembolism occurs frequently in patients with cance

171 Venous thromboembolism occurs in up to one-third of patients wi

172 any major bleeding of 3.07% (2.70-3.44) and thromboembolism of 4.90% (4.43-5.37), and those with ren

173 th a history of HIT (eg, treatment of venous thromboembolism or acute coronary syndrome), preference

174 4-week intervals to elicit information about thromboembolism or bleeding otherwise unknown to the ant

175 outcome was a composite of recurrent venous thromboembolism or major bleeding during the 12 months a

176 to the composite outcome of recurrent venous thromboembolism or major bleeding.

177 (aged >/=75 years) treated for acute venous thromboembolism or stroke prevention in atrial fibrillat

178 luded the studies if their outcomes included thromboembolism or stroke/transient ischemic attacks and

179 rction (OR: 1.44; 95% CI: 1.22-1.70), venous thromboembolism (OR:2.11; 95% CI: 1.70-2.61), acute rena

180 travascular hemolysis, (2) chronic pulmonary thromboembolism, or (3) upregulated hypoxic responses se

181 major bleeding, INR of 4 or greater, venous thromboembolism, or death.

182 major bleeding, INR of 4 or greater, venous thromboembolism, or death.

183 ssociations between statins and first venous thromboembolism outcomes were identified from MEDLINE, E

184 n is based on anticoagulation for those with thromboembolism; oxygen therapy for those with low oxyge

185 autopsy was better at identifying pulmonary thromboembolism (p=0.004).

186 X trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrix

187 ral anticoagulation (OAC) is the mainstay of thromboembolism prevention, and management of anticoagul

188 tay, bed elevation to >/=30 degrees , venous thromboembolism prophylaxis, diet administration, job sa

189 Pulmonary thromboembolism (PTE) is a common disease with a high mo

190 tack, renal insufficiency or failure, venous thromboembolism, pulmonary embolism, and operative compl

191 ert off-target effects causing hypertension, thromboembolism, QT prolongation, and atrial fibrillatio

192 The overall median symptomatic venous thromboembolism rate was 2.48% (IQR 0.84-5.61); rates wa

193 igible for inclusion if they reported venous thromboembolism rates (number of events per follow-up pe

194 cohorts included in the assessment of venous thromboembolism rates and 46 cohorts included in the met

195 Venous thromboembolism rates are low and largely unchanged desp

196 Venous thromboembolism rates varied widely in patients in hospi

197 sfunction and reported that recurrent venous thromboembolism rates were lower with edoxaban than warf

198 Venous thromboembolism recurred in 15 of the 307 patients who r

199 actor XI contributes to postoperative venous thromboembolism; reducing factor XI levels in patients u

200 Although many patients with venous thromboembolism require extended treatment, it is uncert

201 hrough a peripheral intravenous line, venous thromboembolism risk was not elevated if transfusions we

202 ssion, CD39/NTPDase1 enzymatic activity, and thromboembolism risk.

203 .71; 95% CI, 0.51-0.99), 33 vs 38 for venous thromboembolism (RR, 0.85; 95% CI, 0.54-1.34), and there

204 ess syndrome, multiple organ failure, venous thromboembolism, sepsis, and transfusion-related complic

205 art of a larger case-control study of venous thromboembolism, serum levels of 51 proteins implicated

206 alignancy in Patients with Idiopathic Venous Thromboembolism (SOME) trial.

207 The primary outcomes were arterial thromboembolism (stroke, systemic embolism, or transient

208 te primary outcome variables (risk of venous thromboembolism, stroke, or transient ischemic attack) a

209 the risks of treatment are low, but include thromboembolism, the risk of which depends on the dose a

210 elation between medical device infection and thromboembolism; the increase in model clot heterogeneit

211 nticoagulation in patients with acute venous thromboembolism, their benefit-risk ratio is unclear.

212 lts indicate that platelet APP limits venous thromboembolism through a negative regulation of both fi

213 o had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-weight h

214 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban

215 obese or IBD patients with unprovoked venous thromboembolism unless there is a high risk of bleeding,

216 risk factors for 30-day postdischarge venous thromboembolism (VTE) after bariatric surgery and to ide

217 atify risk or provide prophylaxis for venous thromboembolism (VTE) among surgical patients.

218 ve confirmed known risk mutations for venous thromboembolism (VTE) and identified a number of novel s

219 ely investigated for the diagnosis of venous thromboembolism (VTE) and is used routinely for this ind

220 We quantified the risk of venous thromboembolism (VTE) and ischemic stroke (IS) due to st

221 th issues influence the occurrence of venous thromboembolism (VTE) and may impact Medicare reimbursem

222 ecurrence in patients with unprovoked venous thromboembolism (VTE) and may justify stopping treatment

223 s with a first unprovoked symptomatic venous thromboembolism (VTE) are unknown.

224 bomodulin) that increased the risk of venous thromboembolism (VTE) by about 2.3-fold in African Ameri

225 trogens, is associated with recurrent venous thromboembolism (VTE) during anticoagulation.

226 The annual number of US venous thromboembolism (VTE) events, the number of potentially

227 g recurrence risk after an unprovoked venous thromboembolism (VTE) has been developed to identify ind

228 The incidence of pediatric venous thromboembolism (VTE) has been increasing significantly

229 cava (IVC) filters for prevention of venous thromboembolism (VTE) in bariatric surgery is a contenti

230 redicting initial, but not recurrent, venous thromboembolism (VTE) in cancer, a setting in which pred

231 r warfarin for the treatment of acute venous thromboembolism (VTE) in patients with active cancer lar

232 Although rare, the incidence of venous thromboembolism (VTE) in pediatric trauma patients is in

233 meta-analysis to evaluate the risk of venous thromboembolism (VTE) in pregnant women with essential t

234 ylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma patients.

235 Venous thromboembolism (VTE) is a common disease associated wit

236 Venous thromboembolism (VTE) is a leading cause of maternal mor

237 Postpartum venous thromboembolism (VTE) is a potentially fatal and prevent

238 Venous thromboembolism (VTE) is an important complication of co

239 Venous thromboembolism (VTE) is common in cancer patients.

240 Venous thromboembolism (VTE) is common in patients with brain t

241 Appropriate risk stratification for venous thromboembolism (VTE) is essential to providing appropri

242 The risk for venous thromboembolism (VTE) is increased in cancer and particu

243 Venous thromboembolism (VTE) is the second leading cause of dea

244 Venous thromboembolism (VTE) is the third most common life-thre

245 on in patients with cancer-associated venous thromboembolism (VTE) is unknown.

246 our study replicated previously known venous thromboembolism (VTE) loci near the F5, FGA-FGG, F11, F2

247 taking oral anticoagulant therapy for venous thromboembolism (VTE) may use estrogen or progestin horm

248 or cancer in patients with unprovoked venous thromboembolism (VTE) often is considered, but clinician

249 or to unfractionated heparin (UH) for venous thromboembolism (VTE) prophylaxis in patients with sever

250 Venous thromboembolism (VTE) surveillance practices in hospital

251 ents individually risk stratified for venous thromboembolism (VTE) using Caprini scores.

252 tudy has assessed whether the risk of venous thromboembolism (VTE) varies with blunt or penetrating t

253 Donato et al report that treatment of venous thromboembolism (VTE) with anticoagulation does not incr

254 to understand the inherited basis for venous thromboembolism (VTE), a leading cause of cardiovascular

255 associated with an increased risk of venous thromboembolism (VTE), but the association can be confou

256 sma biomarkers for predicting risk of venous thromboembolism (VTE), but thus far, such markers have r

257 Venous thromboembolism (VTE), caused by altered hemostasis, rem

258 erences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality in

259 reast cancer are at increased risk of venous thromboembolism (VTE), particularly in the peridiagnosis

260 Venous thromboembolism (VTE), the third leading cause of cardio

261 ry embolism are collectively known as venous thromboembolism (VTE), which is a common vascular diseas

262 licates platelets as key mediators of venous thromboembolism (VTE).

263 ients are at high risk for developing venous thromboembolism (VTE).

264 erosis may be associated with risk of venous thromboembolism (VTE).

265 complicated by adverse events such as venous thromboembolism (VTE).

266 isk marker for incident and recurrent venous thromboembolism (VTE).

267 diovascular disease risk factors with venous thromboembolism (VTE).

268 e, and transient ischemic attack) and venous thromboembolism (VTE).

269 ENTPD1 polymorphisms associated with venous thromboembolism (VTE).

270 er patients have an increased risk of venous thromboembolism (VTE).

271 rding serious adverse events, such as venous thromboembolism (VTE).

272 K antagonists (VKA) in patients with venous thromboembolism (VTE).

273 in thrombosis and pulmonary embolism (venous thromboembolism, VTE), biomarkers or genetic risk factor

274 The incidence of arterial thromboembolism was 0.4% in the no-bridging group and 0.

275 ervational studies, the pooled RR for venous thromboembolism was 0.75 (95% CI 0.65-0.87; p<0.0001) wh

276 In RCTs, the RR for venous thromboembolism was 0.85 (0.73-0.99; p=0.038) when stati

277 The frequency of recurrent venous thromboembolism was 1.4% (36/2505) in the rivaroxaban gr

278 -up of 7 years, the incidence rate of venous thromboembolism was 18.0/1000 person-years (95% confiden

279 The 6-month cumulative incidence of arterial thromboembolism was 4.7% (95% confidence interval [CI]:

280 Venous thromboembolism was diagnosed in 1141 of 536,423 childre

281 DS2-VASc scores (>/=4), the absolute risk of thromboembolism was high regardless of presence of AF (f

282 The rate of recurrent venous thromboembolism was lower but the rate of major bleeding

283 o significant difference in recurrent venous thromboembolism was seen over the 24-month follow-up per

284 Rates of major bleeding and recurrent venous thromboembolism were low in rivaroxaban-treated patients

285 Rates of major and CRNM bleeding and thromboembolism were low in the two treatment groups.

286 licated recoveries (death, infection, venous thromboembolism) were matched with 12 cases with unevent

287 Careful monitoring for venous thromboembolism when transfusing red blood cells through

288 Venous thromboembolism (which comprised events of pulmonary emb

289 gested to have a protective effect on venous thromboembolism (which includes deep vein thrombosis and

290 death only among patients with acute venous thromboembolism who had a contraindication to anticoagul

291 5 patients with first-ever unprovoked venous thromboembolism who had completed 3 to 12 months of oral

292 rnative to warfarin for patients with venous thromboembolism who require extended treatment for preve

293 r Patients Who Are at High Risk for Arterial Thromboembolism), will help guide periprocedural managem

294 Artery-to-artery thromboembolism with impaired washout at border zones wa

295 who were taking warfarin for previous venous thromboembolism, with a target international normalised

296 ecurrence in patients with unprovoked venous thromboembolism, with no apparent increase of bleeding r

297 aindication to anticoagulation, prior venous thromboembolism within 180 days, or diagnosis of a PE su

298 imals from activated platelet-induced venous thromboembolism without increasing bleeding from injury

299 0.7%; mortality directly attributable to AF (thromboembolism without prophylactic anticoagulation) wa

300 g-term and Initial Anticoagulation in venous thromboembolism (XALIA) was a multicentre, international